tetano
Editor, Senior Moderator
Vaccine. 2010 Jul 23. [Epub ahead of print]
Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, Huang LM, Chang FY, Wang NC, Liu YC, Lee WS, Liu HE, Chen CI, Chen CH.
Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan.
Abstract
We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30mug of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer >==1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30mug of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30mug, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30mug, respectively. This study indicated that one dose of 15mug hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively). Copyright ? 2010. Published by Elsevier Ltd.
PMID: 20659517 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20659517
Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, Huang LM, Chang FY, Wang NC, Liu YC, Lee WS, Liu HE, Chen CI, Chen CH.
Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan.
Abstract
We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30mug of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer >==1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30mug of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30mug, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30mug, respectively. This study indicated that one dose of 15mug hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively). Copyright ? 2010. Published by Elsevier Ltd.
PMID: 20659517 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/20659517